FGFR2 and cholangiocarcinoma: Since CCA is highly heterogeneous, only a limited percentage of patients have mutations or aberrations on targeted genes (under 10% for IDH1/2 mutations and 3–50% for FGFR2 fusion [22]), meaning the limited efficacy of drugs targeting mutated genes.